RevOpsis Appoints Ronil Patel as Chief Business Officer [Yahoo! Finance]
Ocuphire Pharma, Inc. (OCUP)
Company Research
Source: Yahoo! Finance
SAN CARLOS, Calif. June 24, 2024 /PRNewswire/ -- RevOpsis Therapeutics, a next-generation biopharmaceutical company spearheading innovation of multispecific ophthalmic therapies, announced today the appointment of Ronil Patel as Chief Business Officer, effective immediately. In his new role, Patel will be responsible for RevOpsis' global strategy and business development. Patel brings over 15 years of experience in drug development, with a strong track record in early-stage asset management, strategic R&D decisions, and designing fast-to-market strategies. He excels in realizing commercial value, addressing unmet needs, and facilitating strategic transactions and funding for biotech companies. "We are thrilled to welcome Ronil Patel to the RevOpsis team," said Ram Bhandari, interim CEO of RevOpsis. "His extensive experience in the healthcare industry, particularly in the ophthalmic sector, and his strategic vision will be invaluable as we advance our lead asset RO-104 and other p
Show less
Read more
Impact Snapshot
Event Time:
OCUP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCUP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCUP alerts
High impacting Ocuphire Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
OCUP
News
- Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June [Yahoo! Finance]Yahoo! Finance
- Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in JuneGlobeNewswire
- Ocuphire Pharma, Inc. (NASDAQ: OCUP) was upgraded by analysts at Canaccord Genuity Group Inc. to a "strong-buy" rating.MarketBeat
- Ocuphire Pharma, Inc. (NASDAQ: OCUP) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $22.00 to $18.00. They now have a "buy" rating on the stock.MarketBeat
- Ocuphire Pharma, Inc. (NASDAQ: OCUP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
OCUP
Earnings
- 11/13/23 - Beat
OCUP
Sec Filings
- 6/13/24 - Form 4
- 6/13/24 - Form 4
- 6/13/24 - Form 4
- OCUP's page on the SEC website